The 30th Annual Update on HIV Management in Los Angeles, California

Last Modified: Jun 20, 2023 @ 4:12 PM

Program Description

This live course will consist of an in-person component as long as it is safe and practical to do so. There will also be a simultaneous virtual component for those unable to travel.

This live course will focus on recent advances in HIV medicine including updates from CROI 2022, new antiretroviral formulations and strategies, the implications of mRNA vaccines for an HIV vaccine, and the clinical relationship between HIV and COVID-19. This course will feature a case-based panel discussion on antiretroviral.

For those attending in person, proof of vaccination and wearing a mask at all times during the course will be required, as well as any other measure(s) the IAS–USA sets forth to help us ensure our attendees are safe.

Assessment of Needs

Rapid advances in HIV disease management and COVID-19 information require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and COVID-19. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

• Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data from recent HIV literature, including research on new and investigational antiretroviral drugs
• Initiate and monitor HIV prevention intervention strategies, including the use of long-acting injectable preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
• Assess frailty in older people with HIV

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.